

45 **Abstract**

46 **Background:** To increase locoregional and systemic tumor control, a portion of patients with stage III (N2, N3)
47 non-small cell lung cancer (NSCLC) received pulmonary resection after immunochemotherapy in our center.
48 Herein, we assessed the real-world downstage (T, N stage) effectiveness of immunochemotherapy as induction
49 treatment and explored the proper cycle number for stage III (N2, N3) NSCLC.

50 **Methods:** Biopsy confirmed stage III (N2, N3) NSCLC patients who underwent immunochemotherapy between
51 January 1st, 2018, to August 30th, 2019, were identified. Tumor radiologic regression, lymph node down-staging,
52 and pathological response information were collected.

53 **Results:** In total, 16 patients with stage IIIA NSCLC, 30 with stage IIIB NSCLC, 9 with stage IIIC NSCLC (N2,
54 N3 metastasis) were included. After immunochemotherapy, 25/55 (45.5%) patients achieved an objective response.
55 Ultimately, 33/55 (60.0%) patients received lobectomy plus systemic lymphadenectomy, of whom 18/33 (54.5%)
56 obtained major pathological response (MPR) of the primary lesion, and 24 (72.7%) had pathological-confirmed
57 lymph node downstage (N2-3 to N0-1). Notably, four patients had MPR of the primary lesion but without lymph
58 node downstage. At the time of data cutoff (December 30th, 2020), the median follow-up duration was 9.2 months
59 (IQR 8.0-11.7), 24/33 (72.7%) of patients that had pulmonary resection were progression-free, with 30 of them
60 alive. Binary logistics analysis showed that 3-4 induction cycles were favorably associated with MPR than 1-2
61 cycles ($p = 0.017$).

62 **Conclusions:** Immunochemotherapy as induction treatment showed encouraging MPR and lymph nodes
63 down-staging rates in stage III (N2, N3) NSCLC in this study. Prolonged (3-4) cycles of immunochemotherapy
64 were recommended for a better pathological response.

65
66 **Keywords:** stage III non-small cell lung cancer, induction immunochemotherapy, tumor downstage, lymph node
67 downstage, induction cycle, real-world data

68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88

89 **Introduction**

90 Non-small-cell lung cancer (NSCLC) accounts for 80–85% of all lung cancer cases. Approximately 20% of
91 patients with NSCLC are locally advanced disease at diagnosis and are generally considered inoperable. Outcomes
92 remain poor for this subset of patients, with a median progression-free survival of 13 months and 3-year overall
93 survival of 30%. Most locally advanced NSCLC experience disease progression, despite definitive concurrent
94 chemoradiotherapy [1].

95 Anti-PD-1 immunotherapies (IO), which block the binding of the PD-1 receptor and its ligands (PD-L1/2), have
96 been proven to improve the outcomes of patients with advanced NSCLC. Recently, the results of some phase II
97 studies investigating the role of immunotherapy plus chemotherapy[2-4] or dual checkpoint inhibition [5] have
98 been published, which supported the addition of IO in neoadjuvant treatment for patients with resectable stage
99 NSCLC. The NADIM trial [6] assessed the efficacy and safety of neoadjuvant immunochemotherapy followed by
100 surgery and adjuvant nivolumab in stage IIIA NSCLC patients. Down-staging occurred in 90% of cases, and 35
101 (85.4%) of 41 patients survived without recurrence following surgery. The phase II NEOSTAR trial [5]
102 administered three doses of nivolumab with or without ipilimumab as a neoadjuvant regimen in 44 patients with
103 stage I–IIIA NSCLC. MPR rates in the nivolumab and nivolumab plus ipilimumab groups were 17% and 33%,
104 respectively. However, advanced stage III NSCLCs with N2, N3 metastasis were generally excluded from trials
105 respecting neoadjuvant immunochemotherapy due to the initial unresectability.

106 Long-term outcomes from phase III clinical trials of PD-1 inhibitors in previously treated patients with advanced
107 NSCLC demonstrated a 2-year overall survival of 23%-29% and 5-year overall survival of 16%[7, 8]. A
108 subsequent study, the phase III clinical trials PACIFIC, have released its latest outcome that 3-year overall survival
109 of the durvalumab group attained 57.0% versus 43.5% of placebo[9]. The survival advantage with anti-PD-1
110 agents after concurrent chemoradiotherapy in patients with stage III, unresectable NSCLC has been proven. This
111 pattern, which is able to cause long-term tumor regression and potential cure for advanced NSCLC, may render
112 inoperable NSCLC operable. Chaft et al[10] reported five patients with metastatic cancer that underwent tumor
113 resection following ICIs therapy. Surgery was carried out successfully, and 2 (40%) patients had pCR, with four
114 patients remained disease-free 7-23 months postoperatively. However, so far, no study with a sufficient sample size
115 has demonstrated the down-staging (T, N stage) rate in stage III (N2, N3) NSCLC treated by induction
116 immunochemotherapy due to low surgery rate in this cohort. And the long-term survival benefit of surgery
117 following immunochemotherapy in stage III (N2, N3) NSCLC remains poorly elucidated.

118 Furthermore, since the proper cycle number of PD-1 blockades could not be explored from randomized trials,
119 whether prolonged cycles of immunochemotherapy had better efficacy for tumor downstage remains unclear.

120 Immunochemotherapy was administrated in initial stage III NSCLC patients with a potentially curable possibility
121 in our center [11]. And with the aims of increasing both locoregional and systemic control, a portion of patients
122 received radical tumor resection after immunochemotherapy. This retrospective study aimed to assess the
123 real-world downstaging (T, N stage) effectiveness of induction immunochemotherapy for stage III NSCLC with
124 N2, N3 metastatic; figure out the relationship between prolonged cycle and pathological response; with particular
125 attention given to progression-free survival within a year of following up.

126

127 **Materials and Methods**

128 *Study design and patient inclusion*

129 Flow chart of the study design, inclusion, and exclusion criteria used for screening patients, and main oncological
130 outcomes of included patients was shown in Figure 1. The study protocol and methods were reviewed by the
131 institutional ethics committee of the First Affiliated Hospital of Guangzhou Medical University. Patients who
132 underwent at least two cycles of PD-1 immuno-chemotherapy (PD-1 blockades included: Pembrolizumab,

133 Nivolumab, Toripalimab, Camrelizumab or Sintilimab) plus platinum-based chemotherapy to decrease tumor size
134 and down-staging lymph node (intention to surgery) at The First Affiliated Hospital of Guangzhou Medical
135 University between January 1st. 2018 to August 30th. 2019 were identified and included. The data of this patient
136 cohort consecutively retrospectively collected through electronic medical records.

137 Exclusion criteria: patients with small-cell lung cancer (SCLC); patients diagnosed with stage IV NSCLC; or
138 previously treated patients.

139 All patients were followed up until December 30th. 2020.

140 ***Immunochemotherapy and surgical technique***

141 Specimens for cytological and histological examination were obtained via bronchoscopy before induction
142 immune-chemotherapy. PD-L1 expression test was not compulsive in every case. Platinum-based doublet
143 chemotherapy was prescribed every 21 days [12] with PD-1 inhibitors (Pembrolizumab, Nivolumab, Toripalimab,
144 Tislelizumab, Camrelizumab, or Sintilimab). All patients underwent standard diagnostic and staging procedures.
145 Computed tomography (CT) of the brain, chest, and abdomen were performed to exclude distant metastasis. CT
146 scan was administrated every two cycles and at the last planned cycle of immune-chemotherapy. Lymph node
147 status was assessed via PET-CT to first- and re-stage patients. All patients were confirmed to have no targetable
148 driven mutations such as EGFR, ALK, ROS1, and BRAF.

149 More cycles were offered until the tumor was down-staged and became resectable. The resectability of patients
150 was discussed by the multidisciplinary tumor board, which contained an expert group of thoracic surgeons,
151 oncologists, and radiologists. Candidates for operation after induction immunochemotherapy: (1) Confirmed
152 lymph node down-staging (assessed by PET/CT), the operation time will be at the second month after the last
153 cycle of induction immune-chemotherapy; (2) complete cardiovascular examination tests, namely
154 cardiopulmonary exercise test, echocardiogram and coronary angiography, pulmonary function tests showed
155 tolerable cardio-pulmonary function for surgery.

156 All surgeries were initially attempted under video-assisted thoracoscopic surgery (VATS), converting to hybrid
157 VATS or open surgery when necessary. Wedge resection was first performed; residual disease was excluded by
158 frozen section evaluation. Then a lobectomy combined with systematic hilar and mediastinal lymphadenectomy
159 with dissection of stations 2, 4, 7, 8, 9, and 10 during a right pneumonectomy and of stations 4, 5, 6, 7, 8, 9, and 10
160 during a left pneumonectomy. Double sleeve resection was performed in patients that did not tolerate
161 pneumonectomy, and if the main bronchus infiltration by the tumor at the level of origin of the upper lobar bronchi
162 exceeds 2 cm or involvement of pulmonary artery exceeds 3 cm, lung auto-transplantation would be the choice.
163 The anastomosis was covered by the interposition of the vascular pedicled thymic flap, prepericardial fat, thymus,
164 or mediastinal pleura in selected cases.

165 After the operation, the patients were provided with one of the following three regimens as adjuvant treatment after
166 multidisciplinary board discussion according to the original response to chemotherapy and clinical conditions after
167 the operation: (1) Conventional chemotherapy, (2) PD-1 blockade monotherapy, or (3) chemotherapy combined
168 with PD-1 blockade. (Table 3)

169 ***Data collection, evaluation, and statistical analyses***

170 Data were extracted independently by two investigators (HD and HL), and conflicts were adjudicated by a third
171 investigator (WL). Information on all available variables was extracted. The following outcomes of all patients
172 included were used to respectively assess the efficacy and safety of immunochemotherapy: (a)
173 Radiological-regression rate and therapeutic evaluation with RECIST 1.1 standard; (b) Stage change outcomes,
174 defined as the hilar/mediastinal/supraclavicular lymph node regression; (d) pathological regression outcomes; (e)
175 serum tumor markers outcomes; (f) baseline details.

176 The tumor radiological response was evaluated through the Response Evaluation Criteria for Solid Tumors

177 (RECIST) 1.1[13]. Calculation formula of tumor radiologic-regression rate: the longest diameter of the tumor after
178 induction immunochemotherapy treatment, divided by the longest diameter of the tumor before
179 immunochemotherapy treatment. The preoperative and postoperative staging was evaluated in accordance with the
180 8th American Joint Committee on Cancer (AJCC) lung cancer staging manuals on the tumor, node, and metastasis
181 (TNM) staging systems[14]. Pathological analyses were performed on available biospecimens of the surgical
182 group by two senior pathologists. MPR was defined as 10% or less viable tumor remaining on postoperative
183 pathological review[15], while no residual tumor cells found in dissected tissues and lymph node was defined as
184 pCR [15]. The histologic subtype was determined by a review of biopsy specimens obtained before
185 immunochemotherapy for patients with no viable residual tumor.

186 Continuous data are presented as mean and standard deviation and were analyzed with 2-sample Student t-tests for
187 independent data. Categorical variables are given as a count and percentage of patients and compared with the X²
188 or Fisher exact test. All tests were 2-sided, with an α -level of 0.05. SPSS software (SPSS version 25.0; IBM Corp,
189 Armonk, NY) was used for all statistical evaluations. Pearson chi-square or Fisher's exact test were used to
190 comparing proportions. Reported P values are two-sided, and the significance level was set at 0.05 for all analyses
191 unless otherwise noted.

192

193 **Results**

194 *Patients' characteristic*

195 From January 2017 through October 2019, 55 patients with initial N2-3 metastatic NSCLC (16 patients with stage
196 IIIA NSCLC, 30 with stage IIIB NSCLC and 9 with stage IIIC NSCLC) were eligible for inclusion in the study.
197 Detailed baseline characteristics of the included patients were summarized in Table 1. Informed consent of patients
198 was waived considering the retrospective setting.

199 *Tumor and Nodal downstage efficacy of induction immunochemotherapy*

200 For 55 patients with initial stage III (N2-3 metastatic) NSCLC, after induction immunochemotherapy, 25/55
201 (45.5%) patients had a partial response (PR), 23/55 (41.8%) had stable disease (SD), while 4/39 (7.3%) had PD.
202 (Figure 2A, 2B).

203 For 33 of 55 (60.0%) patients that underwent tumor resection (Figure 2C) after immunochemotherapy,
204 pathological-confirmed T stage downstaging occurred in 26 (78.8%) of resected NSCLC, and 24 (72.7%) of
205 patients had pathological-confirmed lymph node downstaging (N2-3 to N0-1). (Figure 2D left) For nine patients
206 with initial N3 NSCLC, only 3 (33.3%) had pathological confirmed supraclavicular lymph node downstaging after
207 immunochemotherapy and underwent surgery. Detailed induction immunochemotherapy regimens and pathologic
208 downstaging of patients that received pulmonary resection were listed in Supplementary Table 1.

209 Twenty-two patients with initial N2-3 NSCLC did not undergo surgery after induction immunochemotherapy, with
210 only 7 of whom had cT stage downstaged and no patients had cN stage downstaged. (Figure 2D right). Detailed
211 oncological outcomes and reasons for not underwent planned surgery were summarized in Supplementary Table 3.

212 *Relationship between immunochemotherapy cycles and pathological response*

213 A binary logistics analysis for MPR including the factors as follow: (1) Histological type; (2) Clinical T stage; (3)
214 Clinical N stage; (4) Induction immunochemotherapy cycles; (Figure 3). The results showed that patients who
215 underwent 3-4 cycles of induction immunochemotherapy were more likely to get MPR compared with

216 conventional two cycles [Exp (B) (95% CI): 14.06 (1.59-124.08); p = 0.017]. However, adding more cycles (≥ 5

217 cycles) did not prone to better pathological response (p=0.845).

218 *Relationship between clinical response, STM, and pathological response*

219 A univariable analysis for MPR, including the factors (1) STM change during induction immunochemotherapy; (2)

220 Clinical response, was conducted. (Figure 3) Serum tumor markers (STM): CEA, CA125, or CA153 decreased $\geq 20\%$
221 than the baseline during the induction immunochemotherapy ($p=0.291$), and partial response after induction
222 immunochemotherapy were associated with MPR ($p=0.129$); however, a significant difference was not reached.

223 *Antitumor response heterogeneity existed between LN and primary lesion*

224 MPR occurred in 18 of 33 (54.5%) resected tumors, of which 10 (30.3%) specimens were considered pCR.

225 Antitumor response heterogeneity existed between lymph nodes and primary tumors. Table 2 showed the clinical
226 response and lymph node downstage status. Of 18 patients considered MPR, 4 (22.2%) patients had no lymph node
227 downstage. While for 19 patients that had lymph node downstage (resected lymph node had no residual tumor cells,
228 7 (36.8%) patients still had residual tumor $> 10\%$ in primary lesion.

229 We present 2 cases with typical antitumor response heterogeneity. (1) Patient 45 was diagnosed with lung
230 squamous cell carcinoma (TNM stage: T3N2M0, stage IIIB) and received 2cycles of induction
231 Pembrolizumab+Paclitaxel liposome+Nedaplatin. The patient then underwent lobectomy of RUL, and the resected
232 specimen achieved 100% pathologic remission (Figure 4A left) but was identified hardly any pathologic remission
233 at resected 4R lymph node (Figure 4A left). (2) Patient 52 was diagnosed with lung squamous cell carcinoma
234 (TNM stage: T4N2M0, stage IIIB) and received 2cycles of induction Sintilimab+Abraxane+Carboplatin. The
235 patient then underwent lobectomy of RUL, and the resected specimen 2R lymph node showed no residual tumor
236 cell (Figure 4B right). However, in the resected specimen primary tumor, only 20% pathologic remission was
237 achieved (Figure 4B left).

238 *Survival outcomes*

239 The Kaplan–Meier curves for progression-free survival (Figure 2E) and overall survival (Figure 2D) in the study
240 population that had surgery were shown in Figure 3. Table 4 showed the postoperative oncological outcomes of 48
241 patients receiving tumor resection. At the time of data cutoff (October 30th, 2020), the median follow-up duration
242 was 9.6 months (IQR 7.9–11.7), 24 of 33 (72.7%) patients that had pulmonary resection were progression-free.
243 Thirty of them (90.9%) still alive at the time cutoff, while two patients died of lymph node relapse 223 days and
244 129 days after surgery, respectively, and one patient died of brain metastasis 255 days after surgery
245 (Supplementary Table 3). The estimated 1-year progression-free survival was 60.14% and the 1-year overall
246 survival was 87.78%. (Table 3)

247

248 **Discussion:**

249 Through immunochemotherapy, 25/55 (45.5%) patients with stage III (N2, N3) NSCLC in the current study had
250 PR. With the aim of increasing both locoregional and systemic control, radical tumor resections were administrated
251 after induction immunochemotherapy in selected 33 patients. Respecting efficacy, MPR occurred in 18 of 33
252 (54.5%) resected tumors and pCR in 10 (30.3%) patients. Compared with the SAKK16/14 study [19], a slightly
253 lower MPR rate (54.5% versus 60%), ORR (45.5% versus 58.1%) and similar 12-month EFS (72.7% vs 71.3%)
254 were shown in this study. However, the calculated MPR rate (54.5% vs. 85.4%) and the estimate PFS (72.7% vs.
255 95.7%) at 12 month was worse than that of the NADIM[20] trial, this might be due to the fact that most of the
256 patients included in this study were with IIIB NSCLC, and potential micrometastasis tends to be accompanied with
257 more advanced stage tumor. To be noted, 16 patients did not undergo surgery, with a majority of them had no
258 tumor downstaging or with tumor progression; thus, the actual response rate of all 55 patients with initial N2-N3
259 lymph node would be even lower.

260 This study also showed that the antitumor activity could be different between metastatic lymph node and primary
261 tumor in patients with unresectable N2/3 NSCLC: 4 patients had MPR of the primary lesion but with no lymph
262 node downstage, while seven patients had no metastatic tumor cells in resected lymph nodes but with pathological
263 response $< 90\%$ in primary lesion. Gao et al.[17] administrated 2cycles of induction sintilimab in resectable

264 NSCLC and identified different responses between primary tumors and lymph node metastases in 18 patients. Liu
265 et al. [18] reported that induction PD-1 blockade could enhance the systemic priming of antitumor T cells to
266 eradicate distant metastases. However, whether primed T cell might be impeded from infiltrating into the lymph
267 nodes or any up-regulated molecular markers affecting the unmatched response remains unknown. The immune
268 microenvironment between primary cancer and metastatic lymph nodes might also lead to this phenomenon, and
269 further study could focus on how to reverse the "local resistance."

270 Notably, a patient (pts 71) in this study experienced progress disease (PD) according to RECIST 1.1 after two
271 cycles of induction immunochemotherapy. However, this patient still had complete pathologic remission (pCR).
272 This may be related to massive fibrosis, lymphocytic infiltration, and peritumoral inflammation occupying the
273 original tumor location after tumor retraction instead of tumor growth. This pseudo-progression was also reported
274 by Tanizaki et al. and Bott et al. [21, 22], in which two pCR patients only had stable disease during treatment of
275 induction IO. The result demonstrated that a proportion of patients with locally advanced NSCLC could benefit
276 from induction IO without initial radiographic tumor shrinkage, even it presented as PD. A more comprehensive
277 response evaluation of induction IO combining CT, SUV value, and serum tumor markers could be useful for
278 identifying this phenomenon before surgery.

279 Considering that some patients have received more than four courses, including ≥ 5 -8 cycles (~30% of N2-N3
280 patients) in this study. We conducted a univariable analysis to investigate the association of clinical factors with
281 MPR. And the result demonstrated that patients who underwent 3-4 cycles of induction immunochemotherapy
282 were more likely to get MPR compared with the conventional two cycles ($p = 0.017$). In clinical trials regarding
283 induction IO in early-stage NSCLC [23, 24], two cycles of IO were administrated before surgery. However, a
284 recent article demonstrated that: a proportion of the top 1% of intra-tumor clonotypes shared with the peripheral T
285 cell receptor repertoire significantly increased after the second cycle of the preoperative anti-PD-1 agent, and the
286 upward trend side remained. The results indicated that the antitumor response is still growing at the second cycle
287 of preoperative PD-1 blockade[25], which reinforced the necessity to extend the induction immunochemotherapy
288 cycle for achieving MPR.

289 Nevertheless, we also found that adding more cycles based on four cycles (≥ 5 cycles) was not associating with the
290 presence of MPR ($p=0.845$). In our center, a strategy of offering more cycles until the tumor was down-staged and
291 became resectable was preferred. And it indicated that some patients might still not respond to induction
292 immunochemotherapy even though sufficient time and cycles were given.

293 In this study, of 33 patients who underwent surgery, 15 (45.5%) reported different levels of pleural adhesion, which
294 can be regarded as a post-immunotherapy response. Chaft et al. [10] included five patients with advanced NSCLC
295 that underwent pneumonectomy after treatment with t-cell checkpoint inhibitors; mediastinal and hilar fibrosis
296 could be seen intraoperatively. Bott et al. [21] investigated pneumonectomy after induction immunotherapy in
297 resectable NSCLC, and more than half of the VATS cases were with perihilar inflammation and fibrosis.
298 Furthermore, the brittleness of the vessels did contribute to the increased difficulty of the operation.

299 Several limitations of this study should be acknowledged. Firstly, this study did not investigate immune-related
300 adverse events of the immunochemotherapy, which influences the tolerance of induction immunochemotherapy.
301 Secondly, we stage each patient before the operation with PET plus contrast-enhanced CT (few of them had
302 EBUS), which might not as accurate as mediastinoscopy; Thirdly, patients in the nonsurgery group could not be
303 staged through surgical specimens, which could bring bias to the integrated downstaging rate considering the
304 pseudo-progression phenomenon and the false positive rate of PET/CT scan stage for lymph nodes.

305

306 **Conclusions:**

307 Immunochemotherapy in patients with stage III (N2, N3) NSCLC is feasible for tumor and nodal downstaging. We

308 believe that the indications of induction immunochemotherapy can be further expanded to initial stage III NSCLC
309 in strictly selected patients, given the acceptable recurrence risk and surgery-related mortality shown above. For
310 initial N2/3 NSCLC, the antitumor response could differ between metastatic nodals and primary tumors. Prolonged
311 cycles of immunochemotherapy (3-4 cycles) were more appropriate for stage III (N2, N3) NSCLC than 1-2 cycles
312 for higher tumor radiologic-regression rate and MPR rate.

313

314 **References:**

315 1. Bradley JD, Paulus R, Komaki R et al. Standard-dose versus high-dose conformal
316 radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without
317 cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a
318 randomised, two-by-two factorial phase 3 study. *Lancet Oncol* 2015; 16: 187-199.

319 2. Shu CA, Gainor JF, Awad MM et al. Neoadjuvant atezolizumab and chemotherapy in
320 patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm,
321 phase 2 trial. *Lancet Oncol* 2020; 21: 786-795.

322 3. Gaudreau PO, Negrao MV, Mitchell KG et al. Neoadjuvant Chemotherapy Increases
323 Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC.
324 *J Thorac Oncol* 2021; 16: 127-139.

325 4. Tfayli A, Al Assaad M, Fakhri G et al. Neoadjuvant chemotherapy and Avelumab in early
326 stage resectable non-small cell lung cancer. *Cancer Med* 2020; 9: 8406-8411.

327 5. Reuss JE, Anagnostou V, Cottrell TR et al. Neoadjuvant nivolumab plus ipilimumab in
328 resectable non-small cell lung cancer. *J Immunother Cancer* 2020; 8.

329 6. Provencio M, Nadal E, Insa A et al. Neoadjuvant chemotherapy and nivolumab in
330 resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase
331 2 trial. *Lancet Oncol* 2020; 21: 1413-1422.

332 7. Gettinger S, Horn L, Jackman D et al. Five-Year Follow-Up of Nivolumab in Previously
333 Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study. *J Clin*

334 Oncol 2018; 36: 1675-1684.

335 8. Horn L, Spigel DR, Vokes EE et al. Nivolumab Versus Docetaxel in Previously Treated
336 Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two
337 Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). J Clin Oncol
338 2017; 35: 3924-3933.

339 9. Gray JE, Villegas A, Daniel D et al. Brief report: Three-year overall survival with
340 durvalumab after chemoradiotherapy in Stage III NSCLC - Update from PACIFIC. J Thorac
341 Oncol 2019.

342 10. Chaft JE, Hellmann MD, Velez MJ et al. Initial Experience With Lung Cancer Resection
343 After Treatment With T-Cell Checkpoint Inhibitors. Ann Thorac Surg 2017; 104: e217-e218.

344 11. Liang H, Yang C, Gonzalez-Rivas D et al. Sleeve lobectomy after neoadjuvant
345 chemoimmunotherapy/chemotherapy for local advanced non-small cell lung cancer. Transl
346 Lung Cancer Res 2021; 10: 143-155.

347 12. Ettinger DS, Wood DE, Aggarwal C et al. NCCN Guidelines Insights: Non-Small Cell Lung
348 Cancer, Version 1.2020. J Natl Compr Canc Netw 2019; 17: 1464-1472.

349 13. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid
350 tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.

351 14. Goldstraw P, Chansky K, Crowley J et al. The IASLC Lung Cancer Staging Project:
352 Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the
353 TNM Classification for Lung Cancer. Journal of Thoracic Oncology 2016; 11: 39-51.

354 15. Pataer A, Kalhor N, Correa AM et al. Histopathologic response criteria predict survival of
355 patients with resected lung cancer after neoadjuvant chemotherapy. J Thorac Oncol 2012; 7:

356 825-832.

357 16. Aupérin A, Le Péchoux C, Rolland E et al. Meta-analysis of concomitant versus
358 sequential radiochemotherapy in locally advanced non-small-cell lung cancer. *J Clin Oncol*
359 2010; 28: 2181-2190.

360 17. Gao S, Li N, Gao S et al. Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC. *Journal of*
361 *Thoracic Oncology* 2020; 15: 816-826.

362 18. Liu J, Blake SJ, Yong MC et al. Improved Efficacy of Neoadjuvant Compared to Adjuvant
363 Immunotherapy to Eradicate Metastatic Disease. *Cancer Discov* 2016; 6: 1382-1399.

364 19. Rothschild S, Zippelius A, Savic S et al. SAKK 16/14: Anti-PD-L1 antibody durvalumab
365 (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small
366 cell lung cancer (NSCLC)—A multicenter single-arm phase II trial. *Journal of Clinical Oncology*
367 2018; 36: TPS8584-TPS8584.

368 20. Provencio M, Nadal E, Insa A et al. OA01.05 Phase II Study of Neo-Adjuvant
369 Chemo/Immunotherapy for Resectable Stages IIIA Non-Small Cell Lung Cancer- Nadim
370 Study-SLCG. *Journal of Thoracic Oncology* 2018; 13: S320.

371 21. Bott MJ, Yang SC, Park BJ et al. Initial results of pulmonary resection after neoadjuvant
372 nivolumab in patients with resectable non-small cell lung cancer. *J Thorac Cardiovasc Surg*
373 2019; 158: 269-276.

374 22. Tanizaki J, Hayashi H, Kimura M et al. Report of two cases of pseudoprogression in
375 patients with non-small cell lung cancer treated with nivolumab-including histological analysis
376 of one case after tumor regression. *Lung Cancer* 2016; 102: 44-48.

377 23. Forde PM, Chaft JE, Smith KN et al. Neoadjuvant PD-1 Blockade in Resectable Lung

378 Cancer. N Engl J Med 2018; 378: 1976-1986.

379 24. Kwiatkowski DJ, Rusch VW, Chaft JE et al. Neoadjuvant atezolizumab in resectable
380 non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter
381 study (LCMC3). Journal of Clinical Oncology 2019; 37: 8503-8503.

382 25. Zhang J, Ji Z, Caushi JX et al. Compartmental analysis of T cell clonal dynamics as a
383 function of pathologic response to neoadjuvant PD-1 blockade in resectable non-small cell
384 lung cancer. Clin Cancer Res 2019.

385

386 **Figure legends:**

387 **Figure 1. Flow chart of the study design, inclusion and exclusion criteria used for screening patients, and**
388 **main oncological outcomes of included patients.**

389

390 **Figure 2. Tumor diameter change, pathological outcomes and postoperative survival outcomes of enrolled**
391 **patients.**

392 (A) Tumor diameter change (%) during curative-intent induction immunochemotherapy by subgroups in 55
393 patients with initial unresectable N2-3 NSCLC, with each bar represents one patient. The 3 rows below the x axis
394 shows clinical characteristics and initial lymph node(s) stage. After induction immunochemotherapy, 25/55 (45.5%)
395 patients had partial response (PR), 23/55 (41.8%) had stable disease (SD), while 4/39 (7.3%) had PD. Of 33
396 patients with initial unresectable N2-3 NSCLC that underwent surgery, MPR occurred in 18 of 33 (54.5%) resected
397 tumors, of which 10 (30.3%) specimens were considered pCR; M, male; F, female; A, lung adenocarcinoma; S,
398 lung squamous-carcinoma; E, lung lymphoepitheliomatoid carcinoma; L, large cell lung cancer; 2, initial N2 stage;
399 3, initial N3 stage. (B up) Pie graph showing the oncological outcomes and (B down) percentage of patients that
400 received surgery. (C left) Clinical stage of patient before and postoperative pathological stage after induction
401 immunochemotherapy of patients in surgery group. (C right) Clinical stage of patient before and after
402 immunochemotherapy of patients in nonsurgery group (D) Kaplan-Meier curves of progression-free survival and
403 (E) overall survival in the patients included (n=33).

404

405 **Figure 3. Clinicopathological characteristics and univariable analysis for major pathological response of**
406 **patients that had surgery.** Patients with serum tumor markers (STM): CEA, CA125, or CA153

407 decreased $\geq 20\%$ than the baseline during the induction IO+C were considered as “STM-decrease”, or
408 else “STM-stable” Four patients were associated with atelectasis or obstructive pneumonitis that
409 extends to the hilar region, making it unevaluable for the clinical response, thus they were not counted.

410

411 **Figure 4. Special cases report demonstrating different response between primary tumor and metastatic**
412 **lymph node.**

413 (A) A patient with age ranges from 55-60 was diagnosed as lung squamous cell carcinoma (TNM stage: T3N2M0,

414 stage IIIB) and received 2cycles of induction Pembrolizumab+Paclitaxel liposome+Nedaplatin. The patient then
415 underwent lobectomy of RUL. The pathologic images shown (A-left) are the primary tumor and large amount of
416 inflammatory cell was found, with 100% pathologic remission been achieved (white arrow); (A-right) hardly no
417 pathologic remission at resected 4R lymph node (white arrow).
418 (B) A patient with age ranges from 55-60 diagnosed as lung squamous cell carcinoma (TNM stage: T4N2M0, stage
419 IIIB) and received 2cycles of induction Sintilimab+Abraxane+Carboplatin. The patient then underwent lobectomy
420 of RUL. The pathologic images shown (B-left) are the primary tumor specimen with 80% residual tumor cell left
421 (white arrow). While the (B-right) resected specimen 2R lymph node showed no residual tumor cell (white arrow).
422

423 Table 1. Baseline Characteristics of patients with initial stage III (N2, N3) NSCLC.

Variable	All patients (n=55)
Age-(Median, Range)	56.60, 37-77
Gender-(Male/ Female)	45/10
BMI (kg/m², x±s)	23.74±3.07
Comorbidities	
Hypertension	11 (20.0%)
Diabetes	9 (16.4%)
Heart diseases	6 (10.9%)
Smoking status-no.(%)	
Never	31 (56.4%)
Former/current	24 (43.6%)
Histological type-no.(%)	
Squamous cell carcinoma	33 (60.0%)
Adenocarcinoma	17 (30.9%)
Large cell lung cancer	1 (1.8%)
Lymphoepithelioma-like carcinoma	3 (5.5%)
Adeno-squamous carcinoma	1 (1.8%)
Tumor, Node, Metastasis staging classification¹-no.(%)	
T1N2M0	1 (1.8%)
T2N2M0	15 (27.3%)
T2N3M0	2 (3.6%) ²
T3N2M0	12 (21.8%)
T3N3M0	4 (7.3%)
T4N2M0	18 (32.7%)
T4N3M0	3 (5.5%) ³
Anti-PD-1 agents-no.	
Pembrolizumab	10 (18.2%)
Nivolumab	11 (20.0%)
Sintilimab	30 (54.5%)
Toripalimab	2 (3.6%)
Camrelizumab	2 (3.6%)
Chemotherapy regimens with IO-no.	
Paclitaxel ² +Platin ³	35 (63.6%)
Pemetrexedisodium+ Platin ³	15 (27.3%)
Gemcitabine+Platin ³	5 (9.1%)
Cycles of induction IO+C-no.	
2	15 (27.3%)
3	18 (32.7%)
4	6 (10.9%)
≥5 (<8)	12 (21.8%)
≥8	4 (7.27%)

424 BMI= body mass index

425 ¹Assessed before induction immunochemotherapy

426 ²Paclitaxel chemotherapy included: Abraxane, Paclitaxel liposome, Docetaxel

427 ³Plantin-based chemotherapy included: Carboplatin, Nedaplatin, Lobaplatin and Cisplatin.

428

429

430 **Table 2. Clinical response and lymph node (LN) downstage status in 33 patients with initial N2-3**

Variable*	No LN downstage (n=9)	LN downstage to N1 (n=5)	LN downstage to N0 (n=19)
Major pathologic response	4 (44.4)	2 (40.0)	12 (63.2)
Complete pathologic response	2 (22.2)	1 (20.0)	7 (36.8)
Residual tumor > 10%	5 (55.5)	3 (60.0)	7 (36.8)

431 **NSCLC that had planned surgery**


432

433

434 Table 3. Postoperative oncological outcomes of patients receiving tumor resection.

	Initial N2-N3 NSCLC that had surgery (n=33)
Adjuvant treatment regimens with IO-no.	
Immunotherapy	3 (9.1%)
Immunochemotherapy	17 (27.3%)
Chemotherapy	12 (36.4%)
Chemo-radiotherapy	1 (3.0%)
Median follow-up time-month (IQR)	9.6 (7.9–11.7)
Recurrence rate at sensor-no. (%)	9 (27.3%)
Recurrence type-no. (%)	
Bone metastasis	2 (6.1%)
Brain metastasis	2 (6.1%)
Lung nodule/mass	2 (6.1%)
Lymph node metastasis	3 (9.1%)
Mortality at sensor-no. (%)	3 (9.1%)

435



2018.01 ~ 2019.10

Patients that had PD-1 inhibitors plus platin-base chemotherapy
n = 191

The remaining patients

n = 71

- Clinical stage I-III NSCLC
- Medical record confirmed curative intent neoadjuvant with surgical planning
- No prior treatment except for IO+C
- Already received at least 2 cycles of IO+C

Excluded:

1. Small cell lung cancer (n = 6)
2. Distant metastasis stage IV NSCLC (n = 39)
3. Postoperative adjuvant IO+C (n = 42)
4. Not medical record confirmed curative intent neoadjuvant IO+C (n = 15)
5. Any prior treatment except for IO+C (n = 18)

Pre-treatment PET/CT or EBUS
confirmed N2/N3 metastasis (n = 55)

Excluded: Pre-treatment PET/CT or EBUS confirmed N0/N1 NSCLC (n = 16)

Observed and followed up for at least 1 year

Patients not underwent planned pulmonary resection (n = 22)



- Diseases progress or Death (n = 5)
- Not progress but still not reach the surgery indication (n = 11)
- Downstage but refuse surgery (n = 2)
- Downstage and still have plan for surgery (n = 4)


Patients underwent planned pulmonary resection (n = 33)

- Major pathological response of primary lesion occurred in:
18 (54.3%) patients
- Lymph node downstage occurred in:
24 (72.7%) patients


Observation index

1. Neoadjuvant IO+C duration (cycles)
2. Diameter change of tumor (using RECIST 1.1)
3. Pathological response
4. Lymph node downstage status (pathological-confirmed)
5. Overall survival and progression-free survival




A


Surgical specimen primary tumor (pts 45)



Surgical specimen 4R lymph node (pts 45)

B

Surgical specimen primary tumor (pts 52)



Surgical specimen 2R lymph node (pts 52)